New data from a Phase 3 clinical trial, UNIFI, evaluating Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical's STELARA (ustekinumab) for the maintenance treatment of adults with moderate-to-severe ulcerative colitis (UC) showed a treatment benefit. The results were presented at ECCO in Copenhagen.
The study met the primary endpoint of a statistically significantly greater proportion of patients in the treatment group remaining in clinical remission at one year compared to placebo. Specifically, 44% of patients treated with subcutaneous injections of STELARA every eight weeks and 38% of those receiving subcutaneous injections every 12 weeks achieved clinical remission at week 44 (52 weeks after intravenous induction) compared to 24% for placebo (p<0.001).
Key secondary endpoints were also met.
Shares are up a fraction premarket.
Now read: Johnson & Johnson: Brace For Impact »
Subscribe for full text news in your inbox